Skip to main content
Fig. 2 | Journal of Biomedical Science

Fig. 2

From: Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma

Fig. 2

SOX17 functions as a transcriptional repressor of NRF2. A Schematic of reporter plasmid construct used in luciferase reporter assay. The NFE2L2 promoter (− 2000 ~  + 10 bp) containing seven SOX17 binding sites was sub-cloned into the pGL4 basic vector. B Schematic of the hypothesis that SOX17-mediated transcriptional repression on NRF2 model. SRY sites: SOX17 binding residues. C Dual luciferase promoter reporter assay was performed to examine the effects of SOX17 wild type (SOX17-WT) or HMG box deletion (SOX17-ΔHMG) overexpression on promoter activity of NFE2L2 in ESCC cells. D Promoter map for NFE2L2 gene. Regions examined with ChIP assay are marked by red circle-backslash symbol. E ChIP-qPCR assay was performed to measure SOX17 binding ability to the promoter region of NFE2L2 in ESCC cells. Data represents mean ± s.e.m. ns: non-significant; *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page